Affiliation:
1. School of Advanced Materials Engineering, Jiaxing Nanhu University, Jiaxing 314001, China
Abstract
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease. Its accurate pathogenic mechanisms are incompletely clarified, and effective therapeutic treatments are still inadequate. Autophagy is closely associated with AD and plays multiple roles in eliminating harmful aggregated proteins and maintaining cell homeostasis. This study identified 1191 differentially expressed genes (DEGs) based on the GSE5281 dataset from the GEO database, intersected them with 325 autophagy-related genes from GeneCards, and screened 26 differentially expressed autophagy-related genes (DEAGs). Subsequently, GO and KEGG enrichment analysis was performed and indicated that these DEAGs were primarily involved in autophagy–lysosomal biological process. Further, eight hub genes were determined by PPI construction, and experimental validation was performed by qRT-PCR on a SH-SY5Y cell model. Finally, three hub genes (TFEB, TOMM20, GABARAPL1) were confirmed to have potential application for biomarkers. A multigenic prediction model with good predictability (AUC = 0.871) was constructed in GSE5281 and validated in the GSE132903 dataset. Hub gene-targeted miRNAs closely associated with AD were also retrieved through the miRDB and HDMM database, predicting potential therapeutic agents for AD. This study provides new insights into autophagy-related genes in brain tissues of AD patients and offers more candidate biomarkers for AD mechanistic research as well as clinical diagnosis.
Funder
scientific research fund of the Zhejiang provincial education department
public welfare research project of Jiaxing science and technology bureau
student research training program of Jiaxing Nanhu University
Reference67 articles.
1. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank;Barker;Alzheimer Dis. Assoc. Disord.,2002
2. Oxidative challenge in Alzheimer’s disease: State of knowledge and future needs;Cervellati;J. Investig. Med. Off. Publ. Am. Fed. Clin. Res.,2016
3. Current and novel therapeutic molecules and targets in Alzheimer’s disease;Kumar;J. Formos. Med. Assoc. Taiwan Yi Zhi,2016
4. The Alzheimer’s Association (2023). 2023 Alzheimer’s disease facts and figures. Alzheimer’s Dement. J. Alzheimer’s Assoc., 19, 1598–1695.
5. The different autophagy degradation pathways and neurodegeneration;Fleming;Neuron,2022